Nomura Sees Big Opportunities to Grow in US Despite Turmoil
Japan's largest brokerage said it's strengthening its focus on the Americas through 'strategic resource allocation,' according to an investor day presentation, which touted the 'big opportunities' there. The firm plans to advance targets for its investment management and wholesale banking businesses by pursuing long-term growth in the Americas, it said.
'Currently, market volatility is increasing due to global tariff negotiations, and the US can be said to be the epicenter of all this,' Chief Executive Officer Kentaro Okuda told investors on Friday. 'However, in our company's global strategy, the US is the most important area rich in business opportunities, and this will not change in the future.'
Nomura is in expansion mode, having recently clinched a $1.8 billion deal to buy Macquarie Group Ltd.'s US and European public asset management business. The firm's optimism toward the US comes against wider sentiments that are more worried about President Donald Trump's trade policies overshadowing global growth prospects.
In its presentation, the Tokyo-based firm also said it aims to boost revenue from trading and investment banking business by 15% to 20% in dollar terms by March 2031. It plans to expand in private credit, structured and solutions, equity trading in Europe and Asia, and international wealth management.
Led by ex-JPMorgan Chase & Co. executive Christopher Willcox, this wholesale banking arm will seek to 'ramp up productivity' of bankers in advisory business as well as global markets sales and trading operations. The division accounts for about half of Nomura's overall net revenue.
Meanwhile, Nomura also introduced a ¥50 billion pretax profit target for its newly created banking division for the year ending March 2031.
Nomura earned a record net profit last fiscal year, joining Wall Street titans in benefiting from trading while enjoying a boom in dealmaking and retail investing in Japan. The firm posted a 72% increase in income before taxes to ¥472 billion in the year ended this March.
At last year's investor day, the management unveiled a target to lift annual pretax profit to more than ¥500 billion by March 2031. It had also identified India and the Middle East as growth opportunities.
This article was generated from an automated news agency feed without modifications to text.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
20 minutes ago
- Mint
Jacob Ramsey transfer: Newcastle United secure £43m deal with Aston Villa for star midfielder
Newcastle United have finalized a £43 million transfer agreement with Aston Villa for the highly-rated midfielder Jacob Ramsey. This move marks a significant coup for the Magpies as they strengthen their squad ahead of the new season. The 24-year-old is set to travel to Tyneside this afternoon to undergo a medical, paving the way for the completion of the transfer. For Aston Villa, this transfer is a strategic move to comply with Financial Fair Play (FFP) regulations, as Ramsey's sale represents profit. Jacob Ramsey is a product of Aston Villa's esteemed academy, having risen through the ranks to become a key figure in their midfield. Since making his senior debut in 2019, Ramsey has amassed over 100 appearances for Villa, scoring 17 goals in 167 matches. He has also represented England at various youth international levels. His consistent performances under Unai Emery last season cemented his reputation as one of the Premier League's brightest young talents. Ramsey's ability to contribute both defensively and offensively makes him a perfect fit for Eddie Howe's high-energy, pressing system. His knack for breaking up play and driving forward with the ball has drawn comparisons to dynamic midfielders who thrive in fast-paced, attacking teams. With Newcastle aiming to push for European qualification, Ramsey's signing is a statement of intent. Newcastle United's pursuit of Jacob Ramsey comes at a crucial time for the club. With uncertainty surrounding the future of star striker Alexander Isak, Eddie Howe has been keen to strengthen the squad to maintain their competitive edge. Ramsey's arrival will provide much-needed depth and quality in midfield, an area where Newcastle have sought improvement. His familiarity with the Premier League and proven track record at Villa make him a low-risk, high-reward signing. For Aston Villa, selling Jacob Ramsey is a pragmatic move to address FFP constraints, especially with key players like Ollie Watkins and John McGinn deemed untouchable. The £43m fee provides financial flexibility, but losing a homegrown talent like Ramsey, who carries the hopes of Villa fans, is bittersweet. Unai Emery, Aston Villa's manager, has been a strong advocate for Ramsey, even fending off interest from Tottenham Hotspur and Newcastle in January 2024. However, injuries and inconsistent form have somewhat stalled his development, making this move to Newcastle a pivotal moment in Ramsey's career. Anthony Elanga (Nottingham Forest, £55m) Antonio Cordero (Malaga, free) Aaron Ramsdale (Southampton, loan) Malick Thiaw (AC Milan, £30m + £4.3m) Lloyd Kelly (Juventus, £20m) Callum Wilson (West Ham, free) Sean Longstaff (Leeds, £12m) Martin Dubravka (Burnley)
&w=3840&q=100)
Business Standard
20 minutes ago
- Business Standard
Glenmark Q1 profit tanks 86% on US settlement hit; revenue stays flat
Glenmark Pharmaceuticals reported an 86 per cent year-on-year decline in consolidated net profit to ₹46.8 crore for the first quarter of FY26. Revenue from operations rose marginally by 0.6 per cent to ₹3,264 crore. Sequentially, profit jumped 917 per cent, while revenue was up 0.2 per cent. The sharp profit fall was due to a provision of $37.75 million made by Glenmark to settle a US antitrust and consumer protection lawsuit with a putative direct purchaser class, subject to court approval. Excluding this, profit before tax and exceptional expenses stood at ₹418.8 crore, down 9.4 per cent year-on-year compared with ₹462 crore last year. Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals, said: 'The recent IGI–AbbVie global licensing agreement for ISB 2001 is a strong validation of our innovation capabilities. We remain confident in our strategy to drive growth across our markets while advancing our branded, specialty, and innovative products.' The results were announced after market hours. Glenmark's stock rose 0.6 per cent to end the day at ₹2,043.95 per share on the BSE. The North America business posted revenue of ₹778 crore for the quarter, down 0.3 per cent year-on-year. Sequentially, it recorded 8.9 per cent growth, driven by market share gains in injectable product launches and partnered products. Revenue from emerging markets stood at ₹572.1 crore, marginally higher than ₹570.8 crore in the same period last year, registering a 0.2 per cent year-on-year increase. The company continues to expect double-digit growth on a constant currency basis. In the European market, revenue was ₹667.8 crore compared with ₹695.7 crore in the same period last year, marking a 4 per cent decline.
Hans India
20 minutes ago
- Hans India
Hyderabad's DEC Infra gets Central government housing contract worth Rs 2,000 crore in New Delhi
Hyderabad: In a significant achievement, the Hyderabad-based DEC Infrastructure and Projects (India) Private Limited has secured a major contract for constructing modern residential facilities for the Central government employees in New Delhi. The company received a Letter of Acceptance from the Central Public Works Department (CPWD) of the Government of India after accepting the tender for carrying out works at a cost of Rs.2,000 crore. The company got the contract for the redevelopment of the general pool residential colony at Sriniwaspuri in New Delhi. Extending gratitude to the Central Public Works Department (CPWD) for awarding the contract, DEC Infrastructure Chairman and Managing Director Anirudh Gupta said the project aims to provide modern residential facilities for the Central government employees. 'It's a proud moment for us to get the contract, reflecting our hard work in ensuring excellent infrastructure facilities both in the private and government sectors,' he explained. The company would construct as many as 3,112 2BHK flats each with 1,100 sft in 16 blocks in 20.86 acres. The high-rise residential units include single basement, stilt and three-level podium parking, a multi-level car parking, a community centre and Central Government Health Scheme (CGHS) dispensary. The redevelopment works also include all development works and services on EPC (Mode-I) basis including comprehensive maintenance and operation of service for five years after completion of construction work. Commenting on the achievement, DEC Infrastructure Whole Time Director Ravinder Gupta said, 'The company's expertise was recognized with an esteemed agreement to lead the high-profile project in the national capital for the benefit of Central government employees.' The company recently bagged Rs 317.32 crore contract for taking up phase-I comprehensive conservation, retrofitting and setting up of service building in North Block in New Delhi. DEC Infrastructure and Projects (India) Private Limited is actively involved in numerous projects worth over Rs.10,000 crore across various sectors in the country. It is presently executing seven projects including Telangana Institute of Medical Sciences (TIMS) in Alwal, Government Medical College in Ramagundam, Medical College and Hospital in Mancherial, Prisons complex in Siddipet, Railway Station at Egmore near Chennai. Two more new projects taken up by the company are the High Court of Telangana and the Railway Station in New Delhi. The Delhi railway is being constructed at a cost of Rs.2,200 crore, while Central Cabinet Minister Chambers in New Delhi at a cost of Rs.295 crore and another contract awarded by NBCC India Limited for constructing a residential colony at Noida at a cost of Rs.2,500 crore.
